Earnings Feed
Start Free
Avalo Therapeutics, Inc.·4

Mar 2, 4:23 PM ET

Riley Jennifer 4

Research Summary

AI-generated summary

Updated

Avalo (AVTX) CSO Jennifer Riley Receives 95,000-Share Option Grant

What Happened
Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics (AVTX), received a derivative award on February 26, 2026: 95,000 shares reported as acquired at $0.00. This was an award/option grant (not an open-market purchase or sale) and carries a multi-year vesting schedule rather than immediate ownership or a cash transaction.

Key Details

  • Transaction date: 2026-02-26; Instrument: derivative award (stock option/award) — 95,000 units at $0.00.
  • Vesting: 25% vests on February 26, 2027; the remainder vests in equal monthly installments over the following three years, subject to continued service (footnote).
  • Shares owned after transaction: not specified in the provided filing.
  • Filing: Form 4 filed 2026-03-02 (appears timely based on the Feb 26 transaction date).
  • No 10b5-1 plan, tax-withholding sale, or cashless exercise noted in the provided details.

Context
This was a compensation-related derivative grant (stock option/award) that vests over time. It is not an immediate purchase or sale and therefore does not directly signal a near-term buy or sell of Avalo stock; such grants are common executive compensation.